This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wijdicks, E. F. Articles by Vermeulen, M. Search for Related Content PubMed PubMed Citation Articles by Wijdicks, E. F. Articles by Vermeulen, M.

Stroke, Vol 20, 1674-1679, Copyright © 1989 by American Heart Association

ARTICLES

Short-term tranexamic acid treatment in aneurysmal subarachnoid hemorrhage

EF Wijdicks, D Hasan, KW Lindsay, PJ Brouwers, R Hatfield, GD Murray, J van Gijn and M Vermeulen
University Department of Neurology, Utrecht, The Netherlands.

Antifibrinolytic treatment for 4 weeks after a subarachnoid hemorrhage has been shown to have no effect on outcome since a reduction in the rate of rebleeding was offset by an increase in ischemic events. To determine if a shorter course (4 days) of antifibrinolytic treatment before the expected onset of ischemic complications might reduce the rate of rebleeding yet avoid ischemic complications, we prospectively studied a series of 119 patients with subarachnoid hemorrhage; 479 patients with subarachnoid hemorrhage from our previous randomized double-blind study (238 treated with placebo, 241 with long-term tranexamic acid) served as historical control groups. At 3 months' follow-up, the outcome of patients treated with short-term tranexamic acid was not different from that of patients treated with long-term tranexamic acid. The rate of rebleeding (24 of 119, 20%) was near that with placebo (56 of 238, 24%). In contrast, the rate of cerebral infarction (33 of 119, 28%) was almost identical to that after long- term tranexamic acid (59 of 241, 24%), although mortality from cerebral infarction was reduced. Compared with historical control groups, treatment with tranexamic acid for 4 days fails to reduce the incidence of rebleeding but still increases the rate of cerebral infarction.

This article has been cited by other articles:

				E. Bennett-Guerrero, W. F. Spillane, W. D. White, L. H. Muhlbaier, S. A. Gall Jr, P. K. Smith, and M. F. Newman {{varepsilon}}-aminocaproic acid administration and stroke following coronary artery bypass graft surgery Ann. Thorac. Surg., May 1, 1999; 67(5): 1283 - 1287. [Abstract] [Full Text] [PDF]